Status:
COMPLETED
Role of suPAR in Periodontitis and CVD
Lead Sponsor:
University of Messina
Collaborating Sponsors:
University of Catania
Conditions:
Metabolic Disturbance
Periodontal Diseases
Eligibility:
All Genders
40-65 years
Brief Summary
soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). Th...
Detailed Description
The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.
Eligibility Criteria
Inclusion
- Presence of at least 15 teeth
- CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm;
- Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
- Presence of ≥40% sites with bleeding on probing (BOP)
Exclusion
- Intake of contraceptives
- Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
- Status of pregnancy or lactation
- Previous history of excessive drinking
- Allergy to local anaesthetic
- Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
Key Trial Info
Start Date :
February 15 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 25 2020
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT04335344
Start Date
February 15 2015
End Date
February 25 2020
Last Update
April 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Messina
Messina, Italy, 98125